프로탈릭스 바이오테라퓨틱스(PLX)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.72 (+0.74%), 시가총액 $0.16B, PER (주가수익비율) 10.58, 52주 최저~최고 $1.35 ~ $3.15.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreeme
프로탈릭스 바이오테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프로탈릭스 바이오테라퓨틱스의 현재 주가는 $2.72 (+0.74%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프로탈릭스 바이오테라퓨틱스의 시가총액은 약 $0.16B입니다. PER은 10.58입니다.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based p